Full foreign ownership is available across most categories but greenfield and brownfield pharma are not treated the same way.
Executive Summary
- India permits 100% FDI in greenfield pharmaceutical projects under the Automatic Route; brownfield investments (acquiring existing manufacturing assets) carry different treatment and should be checked against current sector notifications.
- Hyderabad’s Genome Valley and Pune are the two leading hubs for foreign biotech and life sciences capital, offering dedicated ecosystems for bio-similars, medical devices, and bulk drug manufacturing.
- India’s positioning as a low-cost, high-quality manufacturing base for generics and bio-similars is a distinct commercial advantage independent of the FDI policy itself.
- Regulatory approval from India’s drug regulatory authority operates on a separate track from FDI/FEMA approval securing one does not fast-track the other.
1. Greenfield vs. Brownfield: The Distinction That Determines Your Route
This is the single most important classification question for a foreign pharma investor entering India:
- Greenfield investment (building new manufacturing or R&D facilities from the ground up): generally eligible for 100% FDI under the Automatic Route.
- Brownfield investment (acquiring an existing Indian pharmaceutical company or manufacturing asset): treatment differs and may involve caps or government-route conditions depending on current sector notifications this must be verified at the time of transaction, not assumed from the greenfield position.
Foreign investors evaluating an acquisition (brownfield) versus a new build (greenfield) should treat this as a threshold structuring question before modelling valuation or deal timeline.
2. Why Hyderabad’s Genome Valley Leads Foreign Biotech Investment
Hyderabad has developed a dedicated life sciences ecosystem commonly referred to as Genome Valley that provides plug-and-play infrastructure specifically for foreign biotech firms:
- Dedicated bio-similars and biotech manufacturing clusters, reducing the setup time relative to building standalone infrastructure elsewhere.
- Proximity to India’s broader “Pharmacy of the World” manufacturing base, positioning Hyderabad-based operations within India’s generics and bulk drug export supply chain.
- Established regulatory and clinical trial infrastructure, relevant for foreign firms running India-based trials ahead of a manufacturing or commercial launch.
Pune functions as a complementary hub, particularly for medical devices and firms seeking proximity to Maharashtra’s broader industrial and R&D base.
3. What’s Covered Under 100% FDI in This Sector
| Category | FDI Treatment | Hub |
| Bio-similars manufacturing | 100% (Greenfield, Automatic) | Hyderabad (Genome Valley) |
| Medical devices | 100% (Automatic, most categories) | Hyderabad, Pune |
| Bulk drug manufacturing | 100% (Greenfield, Automatic) | Hyderabad, Pune |
| Brownfield pharma acquisition | Differs verify current cap/route | Case-specific |
4. The Two-Track Approval Reality: FDI Clearance ≠ Drug Regulatory Approval
A common misconception among first-time foreign pharma investors is that FDI/FEMA clearance and drug regulatory approval move on the same timeline. They don’t:
- FDI/FEMA approval governs whether and how foreign capital can enter the Indian entity this is a corporate and foreign exchange matter.
- Drug regulatory approval (manufacturing licenses, clinical trial permissions, product-specific approvals) is administered entirely separately by India’s pharmaceutical regulatory authority and follows its own timeline, documentation, and inspection process.
Securing FDI approval does not shorten or bypass the regulatory approval process, and vice versa these should be planned as two parallel workstreams from the outset, not sequential ones.
5. Structuring Considerations Specific to Life Sciences Investors
- IP licensing structure: Many foreign pharma investors license patents or manufacturing know-how to their Indian subsidiary rather than transferring IP outright this interacts directly with the royalty repatriation channel discussed in Article 4, and should be modelled alongside the corporate structuring decision.
- Local manufacturing partnerships: Some foreign entrants choose a joint structure with an existing Indian manufacturer for the brownfield route, which changes the FDI analysis materially versus a wholly foreign-owned greenfield entity.
- Export orientation: Firms manufacturing primarily for export (rather than the domestic Indian market) may have a different regulatory and incentive profile worth evaluating alongside the core FDI structure.
Practical Pharma & Life Sciences Entry Checklist
- Classify your investment as greenfield or brownfield before modelling deal structure or timeline
- Verify current FDI cap and route treatment for brownfield acquisitions against the latest sector notification
- Evaluate Hyderabad (Genome Valley) vs. Pune based on your specific sub-sector (biotech vs. medical devices vs. bulk drugs)
- Plan drug regulatory approval as a parallel workstream, not a sequential step after FDI clearance
- Model IP licensing/royalty structure alongside corporate structuring, not as an afterthought
- Confirm export vs. domestic market orientation, as this may affect applicable incentives
Strategic Advisory
The greenfield-vs-brownfield classification decision shapes everything downstream valuation, timeline, and even which hub makes sense. GLAN & Co. works alongside your regulatory counsel to align FDI structuring with your drug approval timeline from day one, rather than treating them as separate problems.